Clinical trial
Bismuth-Metronidazole Triple Versus Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Randomized Controlled Trial
NCT04667299 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Bismuth-Metronidazole Triple Versus Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Randomized Controlled Trial
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- December 20, 2020
- Completion date
- December 31, 2021
- Enrollment
- 270 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
helicobacter pylori infection